Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.
Lassa and Junín viruses are the most prominent members of the Arenaviridae family of viruses that cause viral hemorrhagic fever syndromes Lassa fever and Argentine hemorrhagic fever, respectively. At present, ribavirin is the only antiviral drug indicated for use in treatment of these diseases, but...
Main Authors: | Michelle Mendenhall, Andrew Russell, Donald F Smee, Jeffery O Hall, Ramona Skirpstunas, Yousuke Furuta, Brian B Gowen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-10-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3191123?pdf=render |
Similar Items
-
Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.
by: Brian B Gowen, et al.
Published: (2013-01-01) -
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.
by: Brian B Gowen, et al.
Published: (2008-01-01) -
Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever.
by: Lisa Oestereich, et al.
Published: (2014-05-01) -
Antiviral Activity of Favipiravir (T-705) Against Lethal Rift Valley Fever Virus Infection in Hamsters
by: Scharton, Dionna
Published: (2014) -
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever.
by: Amy L Caroline, et al.
Published: (2014-04-01)